Survodutide cuts liver fat in phase 3 MASLD trial, Nature reports
84.2% of survodutide patients hit the 30% liver fat reduction mark versus 24.3% on placebo at week 48.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 7 03:00 ETSource: Nature
The wire
- 01SYNCHRONIZE-MASLD randomized 216 adults with obesity and at-risk MASLD 2:1 to weekly subcutaneous survodutide 6.0 mg or placebo; mean weight change was -12.2% versus -1.0% at 48 weeks.
- 02The glucagon/GLP-1 dual agonist met both co-primary endpoints, positioning it against incretins already used off-label for steatotic liver disease.
- 03Gastrointestinal adverse events clustered during dose escalation; authors cite the 48-week duration and recruitment limited to the United States and Spain as limitations.
From the source
Read at nature.comSurvodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
An Author Correction to this article was published on 25 August 2026